Background: Niacin has proven lipid-modifying efficacy and cardiovascular benefit; however, it is underused because of skin flushing, a process mediated primarily by prostaglandin D(2) (PGD(2)). Laropiprant (LRPT), a PGD(2) receptor (DP1) antagonist that mitigates niacin-induced flushing, has been combined with extended-release niacin (ERN) into a fixed-dose tablet containing 1g of ERN and 20mg of LRPT (ERN/LRPT 1g). In a large-scale (n=∼1600), multinational, 6-month study in dyslipidemic patients, ERN/LRPT 2g produced superior lipid-modifying efficacy vs placebo, whether administered alone or with concomitant statins.
Objective: This Phase III, randomized, double-blind study evaluated the lipid-modifying efficacy of ERN/LRPT alone or added to ongoing statins in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia.
Methods: After a 4-week placebo run-in, patients were randomized to ERN/LRPT 1g (n=322) or placebo (PBO; n=324). After 4 weeks, the dose was advanced to 2 tablets/d (ERN/LRPT 2g or PBO) for 8 additional weeks. End points included effects of ERN/LRPT 2g vs PBO on low-density lipoprotein cholesterol (LDL-C; primary), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and other lipids/lipoproteins.
Results: Relative to PBO, ERN/LRPT 2g produced significant (P < .001) changes in LDL-C (-14.7%), HDL-C (15.9%), TG (-23.4%), LDL-C:HDL-C (-25.5%), non-HDL-C (-16.4%), apolipoprotein (Apo) B (-15.4%), and Apo A-I (5.3%) from baseline to week 12 in the total population. Similar results were observed in patients treated with ERN/LRPT alone or added to ongoing statin.
Conclusion: ERN/LRPT 2g, administered alone or with a statin, produced significant improvements in multiple lipid/lipoprotein parameters in dyslipidemic Asian patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacl.2009.04.048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atherogenic Dyslipidemia Is Critically Related to Aortic Complicated Lesions in Cryptogenic Stroke.
J Atheroscler Thromb
December 2024
Department of Neurology, Juntendo University Urayasu Hospital.
Aims: Atherogenic dyslipidemia (AD) is regarded as a residual risk of cardiovascular diseases characterized by low high-density lipoprotein cholesterol (HDL-C) and high triglyceride (TG) levels and related to the intracranial stenosis of atheromatous thrombotic brain infarction (ATBI). Further, atherosclerosis is possibly related to another stroke subtype, including cryptogenic stroke (CS). In particular, an aortic complicated lesion (ACL) is a notable embolic source of CS, since recurrence of aortogenic brain embolism is not rare.
View Article and Find Full Text PDFReversal of Atherosclerotic Plaque Growth and Vulnerability: Effects of Lipid-Modifying and Anti-Inflammatory Therapeutic Agents.
Biomedicines
October 2024
Faculty of Medicine, University of Patras, 26504 Rio, Greece.
Article Synopsis
- * Effective lipid-lowering therapies, like statins and PCSK9 inhibitors, have been shown to improve clinical outcomes by reducing plaque volume and enhancing its stability.
- * There's a growing need for new treatments that not only lower lipid levels but also target inflammation to stabilize vulnerable plaques and prevent adverse cardiac events.
Olezarsen and Plozasiran in Dyslipidemia Management: A Narrative Review of Clinical Trials.
High Blood Press Cardiovasc Prev
November 2024
Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Article Synopsis
- Cardiovascular diseases are a major cause of death globally, often linked to dyslipidemia and various risk factors, including rare genetic conditions like familial chylomicronemia, which are frequently misdiagnosed.
- Traditional lipid-lowering treatments, primarily statins, have their drawbacks, leading to the exploration of new therapies like Olezarsen and Plozasiran that specifically target lipid metabolism pathways.
- Clinical trials show that these emerging therapies effectively improve cholesterol and triglyceride levels, presenting a promising option for managing dyslipidemia and reducing the risk of atherosclerotic cardiovascular diseases.
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
Am Heart J
August 2024
NewAmsterdam Pharma, Naarden, The Netherlands.
Article Synopsis
- - Obicetrapib is a new medication that lowers harmful LDL cholesterol and increases beneficial HDL cholesterol, potentially helping patients with high cholesterol levels who don’t respond to standard treatments.
- - The BROADWAY and BROOKLYN trials are ongoing studies testing the effectiveness and safety of obicetrapib in patients with cardiovascular disease or genetic high cholesterol issues; over 2,500 participants are involved.
- - Results from these trials, which will examine various cholesterol-related markers and safety concerns, are expected in 2024 and could support the use of obicetrapib in high-risk patient populations.
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review.
Yonsei Med J
January 2024
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Purpose: There are few studies in the literature on the dosage of statin that equivalently reduces low-density lipoprotein cholesterol (LDL-C) compared to an ezetimibe combination and whether such regimens have differences in safety. We compared the lipid-modifying efficacy and safety of 5 mg rosuvastatin/10 mg ezetimibe to those of 20 mg rosuvastatin.
Materials And Methods: A literature search was conducted using the PubMed, EMBASE, Cochrane, Web of Sciences, and SCOPUS databases up to December 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!